EP 1171147 A1 20020116 - MODULATION OF EXCITABLE TISSUE FUNCTION BY PERIPHERALLY ADMINISTERED ERYTHROPOIETIN
Title (en)
MODULATION OF EXCITABLE TISSUE FUNCTION BY PERIPHERALLY ADMINISTERED ERYTHROPOIETIN
Title (de)
MODULATION DER FUNKTION VON ERREGBAREM GEWEBE DURCH PERIPHER VERABREICHTES ERYTHROPOIETIN
Title (fr)
MODULATION DE LA FONCTION D'UN TISSU EXCITABLE PAR ADMINISTRATION PERIPHERIQUE D'UNE ERYTHROPOIETINE
Publication
Application
Priority
- US 0010019 W 20000413
- US 29093899 A 19990413
- US 54722000 A 20000411
Abstract (en)
[origin: WO0061164A1] Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatement of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.
IPC 1-7
IPC 8 full level
A61K 38/00 (2006.01); A61K 38/18 (2006.01); A61K 45/06 (2006.01); A61K 38/22 (2006.01); A61P 9/00 (2006.01); A61P 9/02 (2006.01); A61P 9/10 (2006.01); A61P 25/16 (2006.01); A61P 25/22 (2006.01); A61P 25/28 (2006.01); A61P 25/32 (2006.01); A61P 27/02 (2006.01); A61P 27/06 (2006.01); A61P 29/00 (2006.01); A61P 43/00 (2006.01); C07K 14/00 (2006.01)
CPC (source: EP KR)
A61K 38/1816 (2013.01 - EP); A61K 38/22 (2013.01 - KR); A61P 7/00 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/02 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 9/12 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 25/08 (2018.01 - EP); A61P 25/16 (2018.01 - EP); A61P 25/22 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 25/32 (2018.01 - EP); A61P 27/00 (2018.01 - EP); A61P 27/02 (2018.01 - EP); A61P 27/06 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 37/00 (2018.01 - EP); A61P 39/00 (2018.01 - EP); A61P 43/00 (2018.01 - EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0061164 A1 20001019; AU 4348700 A 20001114; AU 784550 B2 20060504; BG 106058 A 20021229; BG 65353 B1 20080331; BR 0009737 A 20030114; CA 2383940 A1 20001019; CN 1607957 A 20050420; CN 1607957 B 20121010; CR 6501 A 20040415; CZ 20013695 A3 20020213; EA 004766 B1 20040826; EA 200101073 A1 20021031; EP 1171147 A1 20020116; EP 1171147 A4 20030514; HU P0201598 A2 20020928; HU P0201598 A3 20021028; IL 145895 A0 20020725; IL 145895 A 20100531; IS 6104 A 20011011; JP 2003520194 A 20030702; KR 100883232 B1 20090210; KR 101012932 B1 20110208; KR 20020000874 A 20020105; KR 20070094997 A 20070927; MX PA01010177 A 20040910; NO 20014991 D0 20011012; NO 20014991 L 20011115; NZ 514690 A 20040730; NZ 533098 A 20060428; NZ 545478 A 20080430; NZ 560696 A 20100326; PL 352223 A1 20030811; SK 14412001 A3 20020305; TR 200103785 T2 20020621; TR 200402194 T2 20041021
DOCDB simple family (application)
US 0010019 W 20000413; AU 4348700 A 20000413; BG 10605801 A 20011026; BR 0009737 A 20000413; CA 2383940 A 20000413; CN 00808746 A 20000413; CR 6501 A 20011113; CZ 20013695 A 20000413; EA 200101073 A 20000413; EP 00923344 A 20000413; HU P0201598 A 20000413; IL 14589500 A 20000413; IL 14589501 A 20011011; IS 6104 A 20011011; JP 2000610496 A 20000413; KR 20017013093 A 20011013; KR 20077021154 A 20000413; MX PA01010177 A 20000413; NO 20014991 A 20011012; NZ 51469000 A 20000413; NZ 53309800 A 20000413; NZ 54547800 A 20000413; NZ 56069600 A 20000413; PL 35222300 A 20000413; SK 14412001 A 20000413; TR 200103785 T 20000413; TR 200402194 T 20000413